Literature DB >> 34791397

Epidemiology, Diagnosis, and Treatment of Clostridioides difficile Infection in Immunocompromised Children.

Shane J Cross1,2, Theodore H Morton2,3, Joshua Wolf3,4.   

Abstract

Clostridioides difficile infection is very common in immunocompromised children. Management is confounded by frequent asymptomatic colonization, multiple alternative etiologies for gastrointestinal symptoms, and high rates of relapse. Important considerations include indications for testing, appropriate choice of diagnostic tests, antibiotic therapy for initial and subsequent episodes, and primary and secondary prevention.
© The Author(s) 2021. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Clostridioides difficile; children; immunocompromised; immunosuppressed; pediatrics

Mesh：

Substances：

Year:  2021        PMID： 34791397      PMCID： PMC8824809          DOI： 10.1093/jpids/piab078

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN： 2048-7193            Impact factor:   3.164


  57 in total

1.  A hospital-based study of the clinical characteristics of Clostridium difficile infection in children.

Authors:  Jonathan D Crews; Hoonmo L Koo; Zhi-Dong Jiang; Jeffrey R Starke; Herbert L DuPont
Journal:  Pediatr Infect Dis J       Date:  2014-09       Impact factor: 2.129

2.  Clostridioides difficile Infection in Children With Inflammatory Bowel Disease.

Authors:  Abin Chandrakumar; Hussein Zohni; Wael El-Matary
Journal:  Inflamm Bowel Dis       Date:  2020-10-23       Impact factor: 5.325

3.  Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease.

Authors:  Stanley Cho; Elizabeth Spencer; Robert Hirten; Ari Grinspan; Marla C Dubinsky
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-03       Impact factor: 2.839

Review 4.  Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines.

Authors:  Brendan J McMullan; David Andresen; Christopher C Blyth; Minyon L Avent; Asha C Bowen; Philip N Britton; Julia E Clark; Celia M Cooper; Nigel Curtis; Emma Goeman; Briony Hazelton; Gabrielle M Haeusler; Ameneh Khatami; James P Newcombe; Joshua Osowicki; Pamela Palasanthiran; Mike Starr; Tony Lai; Clare Nourse; Joshua R Francis; David Isaacs; Penelope A Bryant
Journal:  Lancet Infect Dis       Date:  2016-06-16       Impact factor: 25.071

5.  Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole.

Authors:  Brittany B Lewis; Charlie G Buffie; Rebecca A Carter; Ingrid Leiner; Nora C Toussaint; Liza C Miller; Asia Gobourne; Lilan Ling; Eric G Pamer
Journal:  J Infect Dis       Date:  2015-04-28       Impact factor: 5.226

6.  Diagnosis and Management of Clostridium difficile Infection by Pediatric Infectious Diseases Physicians.

Authors:  Julia Shaklee Sammons; Jeffrey S Gerber; Pranita D Tamma; Thomas J Sandora; Susan E Beekmann; Philip M Polgreen; Adam L Hersh
Journal:  J Pediatric Infect Dis Soc       Date:  2013-10-17       Impact factor: 3.164

7.  Clostridium difficile infection in hospitalized children in the United States.

Authors:  Cade M Nylund; Anthony Goudie; Jose M Garza; Gerry Fairbrother; Mitchell B Cohen
Journal:  Arch Pediatr Adolesc Med       Date:  2011-01-03

8.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Authors:  Stuart Johnson; Thomas J Louie; Dale N Gerding; Oliver A Cornely; Scott Chasan-Taber; David Fitts; Steven P Gelone; Colin Broom; David M Davidson
Journal:  Clin Infect Dis       Date:  2014-05-05       Impact factor: 9.079

9.  Analysis of Treatment Outcomes for Recurrent Clostridium difficile Infections and Fecal Microbiota Transplantation in a Pediatric Hospital.

Authors:  Aileen M Aldrich; Taylor Argo; Tracy J Koehler; Rosemary Olivero
Journal:  Pediatr Infect Dis J       Date:  2019-01       Impact factor: 2.129

10.  Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.

Authors:  Dale N Gerding; Ciaran P Kelly; Galia Rahav; Christine Lee; Erik R Dubberke; Princy N Kumar; Bruce Yacyshyn; Dina Kao; Karen Eves; Misoo C Ellison; Mary E Hanson; Dalya Guris; Mary Beth Dorr
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.